The accelerated approval program for oncology drugs: celebrating more than 250,000 life-years gained and counting.

Julie PattersonJohn Michael O'BrienJonathan D Campbell
Published in: The American journal of managed care (2024)
This commentary explores how 2 recently published studies evaluating the clinical benefit of the FDA's accelerated approval program for oncology drugs came to different conclusions.
Keyphrases
  • quality improvement
  • palliative care
  • drug administration
  • drug induced
  • systematic review
  • meta analyses